Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus CEPTAZ.
CEFACLOR vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
250-500 mg orally every 8 hours
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."